Emerging Targets and Therapeutics in the Treatment of Psychostimulant Abuse (Volume 69) (Advances in Pharmacology, Volume 69)
Original price was: $369.92.$217.60Current price is: $217.60.
9780124201187, Academic Press, Dwoskin, Linda P.
Original price was: $369.92.$217.60Current price is: $217.60.
Adobooks Marketplace
Related Products
![CEN Exam Secrets Study Guide – CEN Review Book for the Certified Emergency Nurse Exam, Full-Length Practice Test, Step-by-Step Review Video Tutorials: [3rd Edition] (Mometrix Test Preparation) ISBN-13: 9781516713103](https://www.adobooks.com/wp-content/uploads/2025/11/51l6giDMxjL-300x300.jpg)
![ATI TEAS 7 Study Guide 2023-2024: 4 Practice Exams and TEAS Test Review Book for Nursing Entrance [2nd Edition] ISBN-13: 9781637753033](https://www.adobooks.com/wp-content/uploads/2025/11/51EffQg4tsL_ac91834e-0c3f-425e-b049-d7ec8615bb0c-300x300.jpg)
Author: Dwoskin, Linda P.
Brand: Academic Press
Edition: 1
ISBN: 9780124201187
Release Date: 05-03-2014
Package Dimensions: 9.1 x 6.1 x 1.6 inches
Languages: English
Binding: hardcover
Number Of Pages: 656
Details: This new volume of Advances in Pharmacology presents the emerging targets and therapeutics in the treatment of psychostimulant abuse. With a variety of chapters and the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike. Contributions from the best authors in the field An essential resource for pharmacologists, immunologists, and biochemists
User Reviews
Be the first to review “Emerging Targets and Therapeutics in the Treatment of Psychostimulant Abuse (Volume 69) (Advances in Pharmacology, Volume 69)”
Vendor Information
- Store Name: Adobooks Marketplace
- Vendor: Adobooks Marketplace
- 4.71 rating from 7 reviews
![Regulatory proteolytic enzymes and their inhibitors (Proceedings of the 11th FEBS meeting ; v. [6])](https://www.adobooks.com/wp-content/uploads/2025/12/41UI8Z6HnaL-300x300.jpg)
Original price was: $369.92.$217.60Current price is: $217.60.
There are no reviews yet.